Table Info

Sample	Cement powder (g)	Cement liquid (mL)	NPs (mg)	DOX loaded (nmol)	DOX loaded (% w/w)
Blank	0.326	0.167	0	0	0	0
Ø NP	0.326	0.167	0	0	240	0.027
0 µmol/L	0.326	0.167	10	40	0	0
40 µmol/L	0.326	0.167	10	40	80	0.008
80 µmol/L	0.326	0.167	10	40	160	0.017
120 µmol/L	0.326	0.167	10	40	240	0.025
240 µmol/L	0.326	0.167	10	40	480	0.050

Declarations

Acknowledgments

The authors gratefully acknowledge Professor M. Park (McGill university) for providing donating a cell line used in this study and the support of the McGill Orthopaedic fellows and surgeons of the McGill Scoliosis and Spine Group for their assistance in obtaining primary human osteoblasts.

Author contributions

AS: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing—original draft, Writing—review & editing. MMG and MEC: Investigation, Writing—original draft, Writing—review & editing. MHW and DHR: Conceptualization, Funding acquisition, Project administration, Resources, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Human lumbar vertebral tissues were obtained from donors with institutional ethical approval in collaboration with Transplant Quebec. This study complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

AO Spine Young Investigator Research Grant Award 2022 [S-16-138W] awarded to DHR and MHW; Cancer Research Society operating grant 2018-2020 given to MHW; AS received the CIHR CGS-M and FRQS doctoral [318974] scholarships; MEC received the CIHR postdoctoral fellowship award [171258]; DHR is a FRQS Junior 2 Research Scholar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Barzilai O, Fisher CG, Bilsky MH. State of the art treatment of spinal metastatic disease. Neurosurgery. 2018;82:757–69. [DOI] [PubMed]

Harel R, Angelov L. Spine metastases: current treatments and future directions. Eur J Cancer. 2010;46:2696–707. [DOI] [PubMed]

Liang T, Wan Y, Zou X, Peng X, Liu S. Is surgery for spine metastasis reasonable in patients older than 60 years? Clin Orthop Relat Res. 2013;471:628–39. [DOI] [PubMed] [PMC]

Sciubba DM, Gokaslan ZL. Diagnosis and management of metastatic spine disease. Surg Oncol. 2006;15:141–51. [DOI] [PubMed]

Rothrock RJ, Barzilai O, Reiner AS, Lis E, Schmitt AM, Higginson DS, et al. Survival trends after surgery for spinal metastatic tumors: 20-year cancer center experience. Neurosurgery. 2021;88:402–12. [DOI] [PubMed] [PMC]

Kurisunkal V, Gulia A, Gupta S. Principles of management of spine metastasis. Indian J Orthop. 2020;54:181–93. [DOI] [PubMed] [PMC]

Bate BG, Khan NR, Kimball BY, Gabrick K, Weaver J. Stereotactic radiosurgery for spinal metastases with or without separation surgery. J Neurosurg Spine. 2015;22:409–15. [DOI] [PubMed]

Howell EP, Williamson T, Karikari I, Abd-El-Barr M, Erickson M, Goodwin ML, et al. Total en bloc resection of primary and metastatic spine tumors. Ann Transl Med. 2019;7:226. [DOI] [PubMed] [PMC]

Hayashi K, Tsuchiya H. The role of surgery in the treatment of metastatic bone tumor. Int J Clin Oncol. 2022;27:1238–46. [DOI] [PubMed]

10.

Healey JH, Shannon F, Boland P, DiResta GR. PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res. 2003;415:S263–75. [DOI] [PubMed]

11.

Cloyd JM, Acosta FL Jr, Polley MY, Ames CP. En bloc resection for primary and metastatic tumors of the spine: a systematic review of the literature. Neurosurgery. 2010;67:435–45. [DOI] [PubMed]

12.

Roedel B, Clarençon F, Touraine S, Cormier E, Molet-Benhamou L, Le Jean L, et al. Has the percutaneous vertebroplasty a role to prevent progression or local recurrence in spinal metastases of breast cancer? J Neuroradiol. 2015;42:222–8. [DOI] [PubMed]

13.

Sundaresan N, Rothman A, Manhart K, Kelliher K. Surgery for solitary metastases of the spine: rationale and results of treatment. Spine (Phila Pa 1976). 2002;27:1802–6. [DOI] [PubMed]

14.

Ismat A, Walter N, Baertl S, Mika J, Lang S, Kerschbaum M, et al. Antibiotic cement coating in orthopedic surgery: a systematic review of reported clinical techniques. J Orthop Traumatol. 2021;22:56. [DOI] [PubMed] [PMC]

15.

Mensah LM, Love BJ. A meta-analysis of bone cement mediated antibiotic release: overkill, but a viable approach to eradicate osteomyelitis and other infections tied to open procedures. Mater Sci Eng C Mater Biol Appl. 2021;123:111999. [DOI] [PubMed]

16.

Wall V, Nguyen TH, Nguyen N, Tran PA. Controlling antibiotic release from polymethylmethacrylate bone cement. Biomedicines. 2021;9:26. [DOI] [PubMed] [PMC]

17.

Lilikakis A, Sutcliffe MP. The effect of vancomycin addition to the compression strength of antibiotic-loaded bone cements. Int Orthop. 2009;33:815–9. [DOI] [PubMed] [PMC]

18.

Hernigou P, Thiéry JP, Benoit J, Voisin MC, Leroux P, Hagege G, et al. Methotrexate diffusion from acrylic cement. Local chemotherapy for bone tumours. J Bone Joint Surg Br. 1989;71:804–11. [DOI] [PubMed]

19.

Rosa MA, Maccauro G, Sgambato A, Ardito R, Falcone G, De Santis V, et al. Acrylic cement added with antiblastics in the treatment of bone metastases. Ultrastructural and in vitro analysis. J Bone Joint Surg Br. 2003;85:712–6. [PubMed]

20.

Phull SS, Yazdi AR, Ghert M, Towler MR. Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: a review. J Bone Oncol. 2020;26:100345. [DOI] [PubMed] [PMC]

21.

Handal JA, Tiedeken NC, Gershkovich GE, Kushner JA, Dratch B, Samuel SP. Polyethylene glycol improves elution properties of polymethyl methacrylate bone cements. J Surg Res. 2015;194:161–6. [DOI] [PubMed]

22.

Funk GA, Burkes JC, Cole KA, Rahaman MN, McIff TE. Antibiotic elution and mechanical strength of PMMA bone cement loaded with borate bioactive glass. J Bone Jt Infect. 2018;3:187–96. [DOI] [PubMed] [PMC]

23.

Méndez JA, Abraham GA, del Mar Fernández M, Vázquez B, San Román J. Self-curing acrylic formulations containing PMMA/PCL composites: properties and antibiotic release behavior. J Biomed Mater Res. 2002;61:66–74. [DOI] [PubMed]

24.

Shen SC, Letchmanan K, Chow PS, Tan RBH. Antibiotic elution and mechanical property of TiO₂ nanotubes functionalized PMMA-based bone cements. J Mech Behav Biomed Mater. 2019;91:91–8. [DOI] [PubMed]

25.

Letchmanan K, Shen SC, Ng WK, Kingshuk P, Shi Z, Wang W, et al. Mechanical properties and antibiotic release characteristics of poly(methyl methacrylate)-based bone cement formulated with mesoporous silica nanoparticles. J Mech Behav Biomed Mater. 2017;72:163–70. [DOI] [PubMed]

26.

Kweon C, McLaren AC, Leon C, McLemore R. Amphotericin B delivery from bone cement increases with porosity but strength decreases. Clin Orthop Relat Res. 2011;469:3002–7. [DOI] [PubMed] [PMC]

27.

Cyphert EL, Kanagasegar N, Zhang N, Learn GD, von Recum HA. PMMA bone cement composite functions as an adjuvant chemotherapeutic platform for localized and multi-window release during bone reconstruction. Macromol Biosci. 2022;22:e2100415. [DOI] [PubMed]

28.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440–6. [DOI] [PubMed] [PMC]

29.

Krukiewicz K, Zak JK. Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. Mater Sci Eng C Mater Biol Appl. 2016;62:927–42. [DOI] [PubMed]

30.

Sábio RM, Meneguin AB, Ribeiro TC, Silva RR, Chorilli M. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery. Int J Pharm. 2019;564:379–409. [DOI] [PubMed]

31.

Fairag R, Rosenzweig DH, Ramirez-Garcialuna JL, Weber MH, Haglund L. Three-dimensional printed polylactic acid scaffolds promote bone-like matrix deposition in vitro. ACS Appl Mater Interfaces. 2019;11:15306–15. [DOI] [PubMed]

32.

Slane J, Vivanco J, Meyer J, Ploeg HL, Squire M. Modification of acrylic bone cement with mesoporous silica nanoparticles: effects on mechanical, fatigue and absorption properties. J Mech Behav Biomed Mater. 2014;29:451–61. [DOI] [PubMed]

33.

Lee JH, El-Fiqi A, Jo JK, Kim DA, Kim SC, Jun SK, et al. Development of long-term antimicrobial poly(methyl methacrylate) by incorporating mesoporous silica nanocarriers. Dent Mater. 2016;32:1564–74. [DOI] [PubMed]

34.

Khaled SM, Charpentier PA, Rizkalla AS. Physical and mechanical properties of PMMA bone cement reinforced with nano-sized titania fibers. J Biomater Appl. 2011;25:515–37. [DOI] [PubMed]

35.

Shen SC, Ng WK, Shi Z, Chia L, Neoh KG, Tan RB. Mesoporous silica nanoparticle-functionalized poly(methyl methacrylate)-based bone cement for effective antibiotics delivery. J Mater Sci Mater Med. 2011;22:2283. [DOI] [PubMed]

36.

Shen SC, Ng WK, Dong YC, Ng J, Tan RB. Nanostructured material formulated acrylic bone cements with enhanced drug release. Mater Sci Eng C Mater Biol Appl. 2016;58:233–41. [DOI] [PubMed]

37.

Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silicananoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale. 2011;3:4314–22. [DOI] [PubMed]

38.

Cyphert EL, Learn GD, Marques DW, Lu CY, von Recum HA. Antibiotic refilling, antimicrobial activity, and mechanical strength of PMMA bone cement composites critically depend on the processing technique. ACS Biomater Sci Eng. 2020;6:4024–35. [DOI] [PubMed]

39.

Li H, Yu H, Zhu C, Hu J, Du M, Zhang F, et al. Cisplatin and doxorubicin dual-loaded mesoporous silica nanoparticles for controlled drug delivery†. RCS Adv. 2016;6:94160–9. [DOI]

40.

Feng L, Dong Z, Tao D, Zhang Y, Liu Z. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5:269–86. [DOI]

41.

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73:1524–35. [DOI] [PubMed] [PMC]

42.

Alkaraki A, Alshaer W, Wehaibi S, Gharaibeh L, Abuarqoub D, Alqudah DA, et al. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes. Breast Cancer. 2020;27:989–98. [DOI] [PubMed]

43.

Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013;45:2736–48. [DOI] [PubMed]

44.

Han J, Lim W, You D, Jeong Y, Kim S, Lee JE, et al. Chemoresistance in the human triple-negative breast cancer cell line MDA-MB-231 induced by doxorubicin gradient is associated with epigenetic alterations in histone deacetylase. J Oncol. 2019;2019:1345026. [DOI] [PubMed] [PMC]

45.

Tonak M, Becker M, Graf C, Eckhard L, Theobald M, Rommens PM, et al. HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma. Anticancer Res. 2014;34:6459–66. [PubMed]

46.

Koto K, Murata H, Sawai Y, Ashihara E, Horii M, Kubo T. Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors. Oncol Lett. 2017;14:1648–56. [DOI] [PubMed] [PMC]

47.

Chiang CC, Hsieh MK, Wang CY, Tuan WH, Lai PL. Cytotoxicity and cell response of preosteoblast in calcium sulfate-augmented PMMA bone cement. Biomed Mater. 2021;16:055014. [DOI] [PubMed]

48.

Fang J, Shen J, Jiang W, Dong W, Hu Z. Cytotoxicity of polymethyl methacrylate cement on primary cultured metastatic spinal cells. Mol Cell Toxicol. 2016;12:125–32. [DOI]

49.

Moreau MF, Chappard D, Lesourd M, Montheard JP, Basle MF. Free radicals and side products released during methylmethacrylate polymerization are cytotoxic for osteoblastic cells. J Biomed Mater Res. 1998;40:124–31. [DOI]

50.

Greco F, de Palma L, Specchia N, Jacobelli S, Gaggini C. Polymethylmethacrylate-antiblastic drug compounds: an in vitro study assessing the cytotoxic effect in cancer cell lines-a new method for local chemotherapy of bone metastasis. Orthopedics. 1992;15:189–94. [DOI] [PubMed]

51.

Maccauro G, Cittadini A, Casarci M, Muratori F, De Angelis D, Piconi C, et al. Methotrexate-added acrylic cement: biological and physical properties. J Mater Sci Mater Med. 2007;18:839–44. [DOI] [PubMed]

52.

Özben H, Eralp L, Baysal G, Cort A, Sarkalkan N, Özben T. Cisplatin loaded PMMA: mechanical properties, surface analysis and effects on Saos-2 cell culture. Acta Orthop Traumatol Turc. 2013;47:184–92. [DOI] [PubMed]

53.

Fitzgerald AA, Li E, Weiner LM. 3D culture systems for exploring cancer immunology. Cancers (Basel). 2021;13:56. [DOI] [PubMed] [PMC]

54.

Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6:19103. [DOI] [PubMed] [PMC]

55.

Carvalho MP, Costa EC, Miguel SP, Correia IJ. Tumor spheroid assembly on hyaluronic acid-based structures: a review. Carbohydr Polym. 2016;150:139–48. [DOI] [PubMed]

56.

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015;33:1837–43. [DOI] [PubMed]

57.

Mosaad EO, Chambers KF, Futrega K, Clements JA, Doran MR. The microwell-mesh: a high-throughput 3D prostate cancer spheroid and drug-testing platform. Sci Rep. 2018;8:253. [DOI] [PubMed] [PMC]

58.

Yildiz T, Gu R, Zauscher S, Betancourt T. Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. Int J Nanomedicine. 2018;13:6961–86. [DOI] [PubMed] [PMC]

59.

Hsiao AY, Torisawa YS, Tung YC, Sud S, Taichman RS, Pienta KJ, et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials. 2009;30:3020–7. [DOI] [PubMed] [PMC]

60.

Saraiva DP, Matias AT, Braga S, Jacinto A, Cabral MG. Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies. Front Oncol. 2020;10:1543. [DOI] [PubMed] [PMC]

61.

van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2021;288:6095–111. [DOI] [PubMed] [PMC]